XTRA:BAYNPharmaceuticals
Bayer (XTRA:BAYN): Valuation Insights Following Strong Phase III Asundexian Stroke Trial Results
Bayer (XTRA:BAYN) is in the spotlight after reporting successful topline results from its Phase III OCEANIC-STROKE trial for asundexian. The investigational anticoagulant significantly reduced the risk of ischemic stroke without an increase in major bleeding events.
See our latest analysis for Bayer.
Bayer’s upbeat OCEANIC-STROKE trial results for asundexian come amid a period of heightened momentum for the stock. After surging on the news, Bayer’s 7-day share price return jumped 12.4%, with...